| Therapeutic | Camrelizumab |
| Target | PDCD1 |
| Heavy Chain | EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYMMSWVRQAPGKGLEWVATISGGGANTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARQLYYFDYWGQGTTVTVSS |
| Light Chain | DIQMTQSPSSLSASVGDRVTITCLASQTIGTWLTWYQQKPGKAPKLLIYTATSLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQVYSIPWTFGGGTKVEIK |
| 100% seqID Fv Structure | 7cu5 [Fvs: BB] |
| 99% seqID Fv Structure | None |
| 95-98% seqID Fv Structure | None |
| 100% seqID Structure | 7cu5 [Fvs: BB] |
Follow these links to our prediction tools:
| Format | Whole mAb |
| Isotype | G4 |
| Highest Clinical Trial (August '23) | Approved |
| Estimated Status (August '23) | Active |
| Recorded Developmental Technology | na |
| INN Year Proposed | 2016 |
| INN Year Recommended | 2017 |
| Companies Involved | Chinese PLA General Hospital, Hangzhou Cancer Hospital, Incyte Corporation, Jiangsu Hengrui Medicine Co., Nanjing Medical University, Peking University People's Hospital, Sun Yat-Sen University |
| Conditions Approved | Hodgkin's disease |
| Conditions Active | Nasopharyngeal cancer, Non-small cell lung cancer, Oesophageal cancer, Liver cancer, Biliary cancer, Cervical cancer, Cholangiocarcinoma, Colorectal cancer, Endometrial cancer, Fallopian tube cancer, Gastric cancer, Osteosarcoma, Ovarian cancer, Pancreatic cancer, Peritoneal cancer, Renal cell carcinoma, Solid tumours, Urogenital cancer, Diffuse large B cell lymphoma, Breast cancer, Malignant melanoma |
| Conditions Discontinued | na |
| Notes |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]
